Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States.
The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors.
It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S.
Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | 0.00 Increased by +100.00% | -1.69 Increased by +100.00% |
| Mar 20, 24 | -0.21 Increased by +86.18% | -1.51 Increased by +86.27% |
| Nov 13, 23 | 0.32 Increased by +115.46% | -0.60 Increased by +153.33% |
| Aug 11, 23 | -0.39 Decreased by -3.80 K% | -1.68 Increased by +76.79% |
| May 10, 23 | -1.14 Increased by +68.33% | -1.65 Increased by +30.91% |
| Mar 30, 23 | -1.50 Increased by +44.44% | -1.43 Decreased by -4.90% |
| Nov 10, 22 | -2.07 Increased by +71.25% | -1.43 Decreased by -44.76% |
| Aug 11, 22 | -0.01 Increased by +99.86% | -1.44 Increased by +99.31% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 22 | 4.32 M Increased by +2.76 K% | -1.15 M Increased by +89.69% | Decreased by -26.63% Increased by +99.64% |
| Mar 31, 22 | 92.00 K Increased by +441.18% | -9.41 M Decreased by -4.54% | Decreased by -10.23 K% Increased by +80.68% |
| Dec 31, 21 | 104.00 K Increased by +285.19% | -6.07 M Increased by +17.57% | Decreased by -5.84 K% Increased by +78.60% |
| Sep 30, 21 | 132.00 K Decreased by -7.04% | -13.25 M Decreased by -206.36% | Decreased by -10.04 K% Decreased by -229.57% |
| Jun 30, 21 | 151.00 K Decreased by -75.12% | -11.15 M Decreased by -117.80% | Decreased by -7.38 K% Decreased by -775.51% |
| Mar 31, 21 | 17.00 K Decreased by -98.37% | -9.01 M Decreased by -119.47% | Decreased by -52.97 K% Decreased by -13.40 K% |
| Dec 31, 20 | 27.00 K Decreased by -95.96% | -7.37 M Increased by +32.19% | Decreased by -27.28 K% Decreased by -1.58 K% |
| Sep 30, 20 | 142.00 K Decreased by -88.00% | -4.33 M Increased by +9.52% | Decreased by -3.05 K% Decreased by -653.81% |